• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    TG Therapeutics, Inc. - Common Stock (NQ:TGTX)

    49.39 +0.11 (+0.22%)
    Streaming Delayed Price Updated: 10:04 AM EDT, Aug 18, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 62,936
    Open 49.28
    Bid (Size) 49.48 (100)
    Ask (Size) 49.65 (200)
    Prev. Close 49.28
    Today's Range 48.98 - 49.47
    52wk Range 26.76 - 59.30
    Shares Outstanding 154,420,772
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection ↗
    908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences... 
    Via MarketBeat
    News headline image
    TG Therapeutics (TGTX) Q2 2026 Earnings Call Transcript ↗
    BRIUMVI revenue surged 64% year-over-year as patient starts hit record levels. 
    Via The Motley Fool
    Topics Earnings

    Performance

    YTD
    +68.7%
    +68.7%
    1 Month
    -8.5%
    -8.5%
    3 Month
    +25.1%
    +25.1%
    6 Month
    +70.0%
    +70.0%
    1 Year
    +78.1%
    +78.1%

    More News

    Read More
    News headline image
    TG Therapeutics Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    TG Therapeutics (NASDAQ:TGTX) Falls as Q2 Revenue Beats but EPS Misses, Guidance Raised Below Estimates ↗
    Via Chartmill
    TG Therapeutics (NASDAQ:TGTX) Meets Minervini's Trend Template with Accelerating Growth ↗
    Via Chartmill
    TG THERAPEUTICS INC (NASDAQ:TGTX): High-Growth Momentum Meets Minervini Trend Template Technical Strength ↗
    Via Chartmill
    TG THERAPEUTICS INC (NASDAQ:TGTX) Screens as Affordable Growth Play with Strong Revenue Surge and Discounted Valuation ↗
    Via Chartmill
    News headline image
    2 Fast-Growing Pharmaceutical Stocks to Buy Now ↗
    Via The Motley Fool
    The Quest to Repair What Multiple Sclerosis Takes Away
    Via Investor Brand Network
    InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
    Via Investor Brand Network
    TG Therapeutics (NASDAQ:TGTX) Q1 2026 Earnings Beat Revenue Guidance but Miss EPS Estimates ↗
    Via Chartmill
    Topics Earnings
    TG Therapeutics Inc (NASDAQ:TGTX) Shows Strong Growth and Technical Setup for Potential Upside ↗
    Via Chartmill
    TG Therapeutics Inc (NASDAQ:TGTX): An Affordable Growth Stock with Strong Momentum ↗
    Via Chartmill
    TG Therapeutics Inc (NASDAQ:TGTX) Presents a Compelling Momentum Case with Strong Growth and Technical Setup ↗
    Via Chartmill
    TG THERAPEUTICS INC (NASDAQ:TGTX) Q4 2025 Earnings Miss Estimates Despite Strong BRIUMVI Outlook ↗
    Via Chartmill
    Topics Earnings
    News headline image
    The Quest to Repair What Multiple Sclerosis Takes Away
    From BioMedWire
    Via GlobeNewswire
    News headline image
    TG Therapeutics Stock Surges After Drug Trial Update ↗
    Via Benzinga
    News headline image
    Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug ↗
    Via The Motley Fool
    News headline image
    TG Therapeutics (TGTX) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    TGTX Q1 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop ↗
    Via The Motley Fool
    News headline image
    TG Therapeutics (TGTX) Q4 2025 Earnings Transcript ↗
    Via The Motley Fool

    Frequently Asked Questions

    Is TG Therapeutics, Inc. - Common Stock publicly traded?
    Yes, TG Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does TG Therapeutics, Inc. - Common Stock trade on?
    TG Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for TG Therapeutics, Inc. - Common Stock?
    The ticker symbol for TG Therapeutics, Inc. - Common Stock is TGTX on the Nasdaq Stock Market
    What is the current price of TG Therapeutics, Inc. - Common Stock?
    The current price of TG Therapeutics, Inc. - Common Stock is 49.39
    When was TG Therapeutics, Inc. - Common Stock last traded?
    The last trade of TG Therapeutics, Inc. - Common Stock was at 08/18/26 10:04 AM ET
    What is the market capitalization of TG Therapeutics, Inc. - Common Stock?
    The market capitalization of TG Therapeutics, Inc. - Common Stock is 7.63B
    How many shares of TG Therapeutics, Inc. - Common Stock are outstanding?
    TG Therapeutics, Inc. - Common Stock has 8B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.